We will focus our discussion on anti-PD1/PD-L1 mono- and combination therapy in TNBC (Figure 1) given that it is the most immunogenic breast cancer subtype and hence will more likely benefit from treatment with ICIs. The gene discussed is CD274; the disease is breast carcinoma.